Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

Phase 2 Completed 45 enrolled Laboratorio Elea Phoenix S.A. Centro de Investigación Veterinaria Tandil CIVETAN · collab Fundación Hospital de Pediatría Prof. Dr. Juan P. Garrahan · collab Universidad Nacional de Quilmes · collab Universidad Nacional de Salta · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy. IVM safety profile and IVM wide spectrum enables to move forward with the investigation in patients infected by SARS-CoV-2 as a proof-of-concept of its possible use in the management of patients with COVID-19, given the current pandemic situation.

Timeline

Start: 2020-05-18
Primary completion: 2020-09-29
Completion: 2020-09-29

Publications

Krolewiecki A, Lifschitz A, Moragas M, Travacio M, Valentini R, Alonso DF, Solari R, Tinelli MA, Cimino RO, Alvarez L, Fleitas PE, Ceballos L, Golemba M, Fernandez F, Fernandez de Oliveira D, Astudillo G, Baeck I, Farina J, Cardama GA, Mangano A, Spitzer E, Gold S, Lanusse C. Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial. EClinicalMedicine. 2021 Jun 18;37:100959. doi: 10.1016/j.eclinm.2021.100959. eCollection 2021 Jul.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivermectin	Small molecule	600 ug/kg	Oral

Indications

No indication recorded.